88. Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):266-271. doi:10.1016/j.clml.2018.02.004. Epub 2018 Feb 8.Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-FreeRemission in a EURO-SKI Subtrial.Rinaldetti S(1), Pfirrmann M(2), Manz K(2), Guilhot J(3), Dietz C(4),Panagiotidis P(5), Spiess B(6), Seifarth W(6), Fabarius A(6), Müller M(4), PagoniM(7), Dimou M(5), Dengler J(8), Waller CF(9), Brümmendorf TH(10), Herbst R(11),Burchert A(12), Janβen C(13), Goebeler ME(14), Jost PJ(15), Hanzel S(16),Schafhausen P(17), Prange-Krex G(18), Illmer T(19), Janzen V(20), KlausmannM(21), Eckert R(22), Büschel G(23), Kiani A(24), Hofmann WK(6), Mahon FX(25),Saussele S(6).Author information: (1)Department of Hematology and Oncology, University Hospital Mannheim,Heidelberg University, Mannheim, Germany. Electronic address:sebastien.rinaldetti@medma.uni-heidelberg.de.(2)Institut für Medizinische Informationsverarbeitung, Biometrie undEpidemiologie (IBE), Ludwig-Maximilians-Universität, München, Germany.(3)INSERM CIC 1402, CHU de Poitiers, Poitiers, France.(4)Institute for Hematology and Oncology (IHO GmbH), Mannheim, Germany.(5)Laikon General Hospital, National and Kapodistrian University of Athens,Athens, Greece.(6)Department of Hematology and Oncology, University Hospital Mannheim,Heidelberg University, Mannheim, Germany.(7)Evangelismos Hospital, Athens, Greece.(8)Onkologische Schwerpunktpraxis Heilbronn, Heilbronn, Germany.(9)Innere Medizin I, Universitätsklinikum Freiburg, Freiburg, Germany.(10)Uniklinik RWTH Aachen, Aachen, Germany.(11)Klinik für Innere Medizin III, Klinikum Chemnitz, Chemnitz, Germany.(12)Klinik für Innere Medizin, Schwerpunkt Hämatologie, Onkologie undImmunologie, Universitätsklinikum Marburg, Marburg, Germany.(13)Onkologie untere Ems, Leer, Germany.(14)Medizinische Klinik und Poliklinik, Universitätsklinikum Würzburg, Würzburg, Germany.(15)III. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität,München, Germany.(16)Hämatologie, Onkologie und Palliativmedizin, KlinikverbundKempten-Oberallgäu, Kempten, Germany.(17)II. Medizinische Klinik und Poliklinik, UniversitätsklinikumHamburg-Eppendorf, Hamburg, Germany.(18)Gemeinschaftspraxis Dres Mohm und Prange-Krex, Dresden, Germany.(19)Fachärztliche Gemeinschaftspraxis mit Schwerpunkt Hämatologie und Onkologie, Dresden, Germany.(20)Medizinische Klinik und Poliklinik III, Universitätsklinikum Bonn, Bonn,Germany.(21)Gemeinschaftspraxis Drs Klausmann, Aschaffenburg, Germany.(22)Onkologische Schwerpunktpraxis Esslingen, Esslingen, Germany.(23)Hämatologie, Onkologie und Palliativmedizin, Vivantes Klinikum Neuköln,Berlin, Germany.(24)Klinik für Onkologie und Hämatologie, Klinikum Bayreuth, Bayreuth, Germany.(25)Bergonié Cancer Institute, INSERM Unit 916, University of Bordeaux, Bordeaux,France.INTRODUCTION: Tyrosine kinase inhibitors (TKIs) can safely be discontinued inchronic myeloid leukemia (CML) patients with sustained deep molecular response.ABCG2 (breast cancer resistance protein), OCT1 (organic cation transporter 1),and ABCB1 (multidrug resistance protein 1) gene products are known to play acrucial role in acquired pharmacogenetic TKI resistance. Their influence ontreatment-free remission (TFR) has not yet been investigated.MATERIALS AND METHODS: RNA was isolated on the last day of TKI intake fromperipheral blood leukocytes of 132 chronic phase CML patients who discontinuedTKI treatment within the European Stop Tyrosine Kinase Inhibitor Study trial.Plasmid standards were designed including subgenic inserts of OCT1, ABCG2, andABCB1 together with GUSB as reference gene. For expression analyses, quantitativereal-time polymerase chain reaction was used. Multiple Cox regression analysiswas performed. In addition, gene expression cutoffs for patient riskstratification were investigated.RESULTS: The TFR rate of 132 patients, 12 months after TKI discontinuation, was54% (95% confidence interval [CI], 46%-62%). ABCG2 expression (‰) was retained asthe only significant variable (P = .02; hazard ratio, 1.04; 95% CI, 1.01-1.07) inmultiple Cox regression analysis. Only for the ABCG2 efflux transporter, asignificant cutoff was found (P = .04). Patients with an ABCG2/GUSB transcriptlevel >4.5‰ (n = 93) showed a 12-month TFR rate of 47% (95% CI, 37%-57%), whereaspatients with low ABCG2 expression (≤4.5‰; n = 39) had a 12-month TFR rate of 72%(95% CI, 55%-82%).CONCLUSION: In this study, we investigated the effect of pharmacogenetics in the context of a CML treatment discontinuation trial. The transcript levels of theefflux transporter ABCG2 predicted TFR after TKI discontinuation.Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.DOI: 10.1016/j.clml.2018.02.004 PMID: 29510895 